Latest News | Natco Pharma Gets Nod for Generic Everolimus Tablets

New Delhi, Jan 30 (PTI) Natco Pharma Ltd on Thursday said it has received approval from the US health regulator for its generic version of Everolimus tablets for oral suspension indicated for patients with tuberous sclerosis complex.

The approval is for the Abbreviated New Drug Application (ANDA) for Everolimus tablets for oral suspension (TFOS) of strengths 2mg, 3mg and 5mg, Natco Pharma said in a regulatory filing.

Also Read | Kolkata Fatafat Result Today: Kolkata FF Result for January 30, 2025 Declared, Check Winning Numbers and Result Chart of Satta Matka-Type Lottery Game.

The drug is a generic version of AFINITOR DISPERZ by Novartis Pharmaceutical Corporation, it added.

"NATCO's marketing partner for the ANDA, Breckenridge Pharmaceutical, Inc plans to launch the product immediately in the US market," the company said.

Also Read | Shillong Teer Results Today, January 30 2025: Winning Numbers, Result Chart for Shillong Morning Teer, Shillong Night Teer, Khanapara Teer, Juwai Teer and Jowai Ladrymbai.

Everolimus TFOS is indicated in adult and paediatric patients aged one year and older with tuberous sclerosis complex (TSC) for the treatment of Subependymal Giant Cell Astrocytoma (SEGA), a rare form of benign tumour, that requires therapeutic intervention but cannot be curatively resected, it said.

Everolimus tablets for oral suspension (TFOS), 2mg, 3mg and 5mg, had estimated sales of USD 112 million in the US for 12 months ending Sep'24 as per industry sales data, Natco said.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)